Hazrath Hameed Shah and Hazrath Muhib Shah Dargha committee is to use its resources towards betterment of society improving the educational and technical skills of the students,

Hazrath Hameed Shah and Hazrath Muhib Shah Dargha Committee is a subsidiary of Karnataka Wakf Board. The Committee manages the affairs of Hameed Shah Complex and other assets.

The objective of the committee is to use its resources towards betterment of society improving the educational and technical skills of the students, providing medical assistance to the poor and helping the needy.

In pursuance of its objectives, the committee has rendered following services and established institutions:

HHS & HMS ITI: This institute imparts education to about 200 students in various technical skills such as A.C Technology, electrician, Electronic engineering, Mechanical Engineering and welding technology.

HHS & HMS Girls Hostel: This hostel is meant for the girls coming from different parts of the state and the nation to pursue studies in different educational institutions in Bengaluru. The hostel accommodates 150 students.

Dialysis Centre: The committee has set up a dialysis unit, which provides dialysis facility free of cost to about 30 persons a day. Dialysis treatment in Private costs about Rs. 1,500/- per head.

Urban Health Centre: The Committee runs an Urban Health Centre in collaboration with BBMP providing free Medical Consultancy and free medicine. On an average, daily 150 patients avail this benefit.

V.K Obaidullah School: This school was earlier adopted by a business group. The group got into legal entanglement and the financial assistance from them abruptly stopped creating panic in Students, parents, teachers and staff and the locality. There were 1800 students in the sehool coming from the poorest of poor in the society. Understanding the gravity of the situation, the committee, responded to the appeals from the local social workers and leaders, adopted the school and running it successfully at an estimated expenses of Rs.1,00,00,000/- per annum. Hon’ble Education Minister Sri Suresh Kumar who visited the school was highly impressed and appreciated the efforts of the committee.

Besides, the following proposals are on hand for implementation:

PSI Training (Police Sub- Inspector Training): Training to prepare candidates for competitive examinations. In this regard, the committee plans to provide free coaching, training & accommodation with food for deserving candidates to those who wish to appear for the selection of Police- Sub Inspector in the next two months (The Govt of Karnataka have announced selection for the post of 224 Sub- Inspectors). It is also envisaged to make this programme ongoing for giving similar training to both the male and female candidates appearing for various posts under State & Central Govt.

The Govt Skill Development programme (Chief Minister’s Kausalya Karnataka Yojane): This is one of the ambitious programs of the Government to ensure employment oriented skill development of youth. There are 1600 courses, The Govt of Karnataka was pleased to grant accreditation to the institution. The institution has already began training for Dialysis Technician, General Duty Assistant, and Home Health aid. Further, it will be expanded to cover important courses like armed security guard, driving, fashion Designer, Beautician, Horticulture, farming etc. SSLC failed candidates also can acquire the skill through training and obtain certificate issued by the Government which will give them openings in various govt, Semi Govt & Corporate sectors.

The committee aims to extend this training to minimum 1000 candidates per year and also to start these trainings in various localities across the state, The committee envisions that nobody should remain unskilled and unemployed.

Blood Bank: The poor are finding it very difficult to get blood when in necd. They have to run around. At times, they do not get the blood. Even if they get each bottle of blood costs Rs.1,800/- In order to enable the poor to get the blood free of cost and without tension, a Blood Bank will be established The donors would be motivated and encouraged to donate blood. The blood so collected shall be given to the needy free of cost. In this connection the committee desires toappoint Doctors: MBBS, MD, Pathology or MBBS, DCP, In Technical Supervisor: BSc. MLT, Technician: DMLT, In Staff Nurse: GNM, Social Worker: MSW Interested may please contact the given numbers.

All the above 3 programme require huge funds. Therefore, the committee seeks liberal donations from Philanthropists. As these programmes besides generating employment would also empower the deprived clsses, the committee appeals to the NGO’s to kindly create awareness so that maximum candidates undergo skill development training.

Ph No. Office: 080-43705786, Education Convener: 9845453355, Special Officer – 9886925171. Assistant: 6360623151.

City Today News
9341997936

Aditya Birla Sun Life Insurance presents DigiShield – First-of-Its-Kind Fully Customizable Term Plan

Aditya Birla Sun Life Insurance presents DigiShield – First-of-Its-Kind Fully Customizable Term Plan
A hyper-personalized plan to suit individual protection needs
Industry first offering of whole life cover with sum assured reduction option

Aditya Birla Sun Life Insurance (ABSLI), the life insurance subsidiary of Aditya Birla Capital Limited (ABCL), announced a hyper-personalized term plan, ABSLI DigiShield Plan, to cater to the unique protection needs of customers. This single plan will offer multiple plan options, added benefits linked to life stages, joint life protection, critical illness cover and rider options to tailor-make a distinctive protection solution, offering a comprehensive financial safety net for the customers and their loved ones.

People have various protection needs during different stages of their life and the hyper-flexibility offering of this plan helps to curate a protection strategy that aligns with their specific needs. Besides offering death benefit and acting as an income replacement tool, ABSLI DigiShield plan assists in comprehensive financial planning.

Unlike traditional term plans, this plan allows a customer to enjoy its benefits during their lifetime through the survival benefit option. Further, it provides a unique flexibility to reduce the sum assured at a pre-defined retirement age, allowing customers to align their cover as per their outstanding liabilities and the life stage. This whole-life cover with sum assured reduction feature is a first-of-its kind in the life insurance industry which offers life coverage until age 100 years.

Along with these fully customizable offerings, this plan also provides various premium paying terms, policy tenures and death benefit pay-out options to satisfy unique customer requirements. This holistic plan mitigates liabilities, provides protection to loved ones, and supports retirement and legacy goals.

Commenting on the launch, Mr. Kamlesh Rao, MD & CEO, Aditya Birla Sun Life Insurance, said, “Recent uncertain times have generated a need for a resilient financial cover with customized offerings. 2021 would be the year of hyper-personalization and at ABSLI, we aim to offer solutions which evolve with changing needs and lifestyles of our customers. ABSLI’s DigiShield Plan is one of a kind offering that stands as testimony to our customer-centric ethos. Now, our new-age customer will be empowered to tailor make a comprehensive solution through the various personalization features and carve a protection policy which is a precise fit for self and family”.

Unique benefits offered by the DigiShield plan:
• Sum assured reduction option with whole life cover – This option offers life coverage until age 100 years and also allows the customer to reduce the sum assured by 50% or 25% at a pre-determined retirement age. This unique flexibility allows customers to choose high sum assured in their earning years and reduce their life cover during their retirement years. It makes the offering ideal for salaried customers or people who have to manage their liabilities effectively.
• Survival income on attaining Age 60 years – This option provides monthly income to the customer on attaining Age 60 years and takes care of retirement income needs. Life cover continues throughout the policy term and the nominee is paid lumpsum benefit of sum assured, less survival benefits paid, in case of any unfortunate event. This option ensures need for life protection & retirement income is taken care under one plan.
• Income Benefit option – This option provides support to the dependent members of the customer in his/her absence by replacing the lost income with a 1.25% of Sum Assured as fixed monthly income or increasing monthly income at 5% (simple) per annum for a period of 10/15/20 years, as chosen by the customer at inception of the policy.
• Level cover option – The nominee is paid the absolute amount equal to the sum assured on death, in lump sum.

• Customize the plan based on your needs: DigiShield plan offers 10 plan options with a variety of benefits to suit every individual’s requirements. Some of the options that one can select from are:
• Type of cover (level & reducing)
• Tenure of the policy (To Age 85 & Whole Life)
• Premium payment term (Single, Limited & Regular)
• Death benefit pay-outs (Lump sum, Monthly income and Lump sum plus Monthly income)
• Accelerated Critical Illness (ACI) benefit: Secured protection against 42 critical illnesses by opting for the Accelerated Critical Illness (ACI) Benefit option with additional premium payment.
• Cover for your spouse: Now one can cover their partner’s life under the same plan by availing of the Joint Life Protection option.
• Multiple rider benefits: A comprehensive protection plan can be created by opting for additional protection through multiple riders by paying additional premiums.
• Enhance protection cover without medical: One can avail flexibility to increase the cover amount on specific events like marriage, childbirth or on availing house without undergoing fresh medical or underwriting, just by intimating us on any of these events.

City Today News
9341997936

3000 Beedi Workers across Tamil Nadu appeal for the Hon’ble PM’s empathy and request him to roll back the proposed amendments to the COTPA, 2003

Chennai, March 2nd, 2021: The Ministry of Health, Government of India, on 1.1.2021, has proposed to add several stringent amendments to the already harsh rules of the ‘Cigarettes and other Tobacco Products (Prohibition of Advertisement and Regulation of Trade and Commerce, production, Supply and Distribution) Act’, 2003, popularly known as Cigarette & Other Tobacco Products Act (COTPA). If these proposed amendments become laws within this act, the 200 year old, ‘Hand-Made in India’ Beedi industry, an indigenous cottage industry, is at risk of overnight closure, and the livelihood of over thirty million workers associated with this industry is in grave peril. Some of the key issues of these rigorous amendments are as follows :

Prohibition of printing the Brand name on the Beedi bundle, pack or carton, thus stripping a legal product of its unique and recognisable identity.
The number of Beedis hand-packed in a bundle to be mandated by the government.
Mandatory purchase of a government issued special Trade License by the smallest of village shopkeepers, street vendors and hawkers for selling Beedis.
Mandatory printing of the Date of manufacture and Maximum Retail Price even on a tiny, hand wrapped, conical pack, 85% of which is already covered by a previously mandated, dire, pictorial warning.
Over and above the existing, absolute prohibition of all forms of retail advertisement and promotion under COTPA 2003 , the proposed new amendments seek to impose even stricter measures, like the prohibition of displaying the brand, or even the product name on the warehouse notice board where it is stored, or at the shop from where it is to be sold, and the prohibition of any type of brand name or logos on the Beedi bundle, pack or carton.
In case of a failure to follow these rigorous rules, wilfully or erroneously, the amendments seek to impose severe punishments and penalties, under both the civil and the criminal codes, and range from seven year jail terms to the highest level of monetary fines.

While the Beedi industry is already fully compliant with the existing, stipulated regulations of COTPA, to be compliant with the new, harsher amendments proposed to COTPA 2003, is extremely challenging, if not impossible, for a small scale , hand-made, cottage industry. The imposition of these proposed amendments and restrictions on this totally natural, indigenous, ‘Hand-Made in India’ product will have a severe and immediate effect on the livelihoods it sustains across the remotest parts of India, where there is no viable alternative employment currently. These new provisions of COTPA may well cause the closure of the Beedi industry, and drive over 30 million workers into unemployment, forced migrations, and extreme poverty. There are eight and a half million home based Beedi rollers across India, of whom six and a half million are women. Mostly housewives, mothers and grandmothers, these multi-generational women earn their livelihood rolling beedis from home while their husbands go out to work, and their children attend school. This essential income enables them to feed, clothe and educate their children, especially daughters, who in the absence of this earning would be forced to go to work as underage domestic help or beg at street corners. Seven million women and tribal people are employed in Tendu leaf plucking in remote forested areas across several states. The cultivation and harvesting of native tobacco used in Beedis employs more than four million farmers and farm workers. Seven and a half million small shopkeepers earn their livelihood by selling Beedis in semi urban and rural areas. If the proposed amendments to COTPA were to become law, Beedi sales are certain to nose dive and fall to a much greater degree as compared to the fall in sales of machine-made Cigarettes and Chewing Tobacco, which do not provide the huge employment that the Beedi industry does. The resultant fall in Beedi production and its deeply negative impact on Beedi employment, threatens to push 30 million workers down into penury instead of helping their next generation rise up to a better life. With this in mind, Beedi Workers across India have been appealing to the Hon’ble Prime Minister to save their livelihoods by keeping Beedis out of the ambit of these new amendments to COTPA, or to have a separate legislation for them within COTPA which is sensitive to their product and situation, and distinct from the laws governing machine-made Cigarettes and Chewing Tobacco.
Worth noting too is the fact that Women Beedi rollers make Beedis at home voluntarily, and have long been regarded as an icon of ‘Atmanirbhar’ India. There is as yet no viable home-based employment alternative available to these six and a half million Beedi women rollers. This hand-made, humble product, often termed a ‘poor man’s luxury’ has not just been a quiet income provider for rural households, it has also been a silent enabler for women beedi rollers to remain financially independent, retain their self-respect and self-reliance, and help their next generation move one step closer to a better life. It is incumbent on the government to keep this unique, situational context of the Beedi industry in mind while giving balanced thought to the exigencies of public health, the sheer magnitude and scale of beedi workers’ employment, and the existential crisis that will be unleashed upon the workers’ livelihoods by the imposition of ever more stringent COTPA laws, especially in the wake of the damage already wreaked by the COVID pandemic.

City Today News
9341997936

B.Tech Admissions 2021 Open atAmrita Vishwa Vidyapeetham

  • In a unique initiative, students can qualify for admission to the varsity’s engineering programmes through its examination called Amrita Engineering Entrance Examination (AEEE) or any of the four specified eligibility exams
  • AEEE 2021 will be conducted online in three phases in April, May and June

March 3, 2021: Amrita Vishwa Vidyapeetham – ranked the 4th Best Overall University in India in the 2020 National Institution Ranking Framework (NIRF) – has announced that admissions are open for its futuristic B.Tech. programmes that offer promising careers in Robotics and Automation, Internet of Things (IoT), Cyber Security, Artificial Intelligence, Aerospace Technology and more.

In a first, students can now qualify for admission to Amrita Vishwa Vidyapeetham’s engineering programmes by acing its international examination called Amrita Engineering Entrance Examination (AEEE), or any of the four eligibility exams including Remote Proctored Examination (CBT or RPE) or JEE Mains 2021 or SAT or Pearson UG Entrance Examination Score (PUEE). The varsity is adhering to the JEE Mains pattern for AEEE – Engineering 2021 Centre Based Test.

The eligibility for appearing in the AEEE test is 12th class or equivalent from a recognized board with not less than 55% in Physics, Chemistry & Mathematics separately, and an aggregate minimum of 60% in Physics, Chemistry and Mathematics. Candidates seeking admission should be born on or after 1st July 2000.

AEEE 2021 will be conducted online in three phases in April, May and Junefor admissions to B.Tech. programs at four campuses of Amrita Vishwa Vidyapeetham located at Amritapuri (Kerala), Bengaluru, Chennai and Coimbatore. Eligible students can participate in any phase of the online/offline test to qualify for admission. The same examination is also conducted offline. The choice of the examination mode lies with the candidate.Maximum three attempts would be allowed for a student, and the best score considered for ranking.

Once a candidate clears any of the given eligibility examinations, an online counselling session will be conducted individually to discuss the prospective engineering programs available, based on the grade. Over 200 students from Amrita Vishwa Vidyapeetham get the opportunity to study abroad each year under various programs.

For more details, please refer to the link: https://www.amrita.edu/btech

City Today News
9341997936

Bharat Biotech Announces Phase 3 Results of COVAXIN®

Bharat Biotech Announces Phase 3 Results of COVAXIN®:
India’s First COVID-19 Vaccine Demonstrates Interim Clinical
Efficacy of 81%
 Data from 25,800 participants, received vaccine or placebo in a 1:1 ratio showed that
the vaccine candidate was well tolerated.
 COVAXIN® demonstrated 81% interim efficacy in preventing COVID-19 in those without
prior infection after the second dose.
 Clinical trial to continue through to final analysis at 130 confirmed cases in order to gather further data and to evaluate the efficacy of COVAXIN in additional secondary
study endpoints.

Hyderabad, India, 03, March, 2021: Bharat Biotech, a global leader in vaccine innovation, developing vaccines for infectious diseases, today announced the first interim analysis of its BBV152 (COVAXIN®). The whole virion inactivated COVID-19 vaccine candidate demonstrated an interim vaccine efficacy of 81% in its Phase 3 clinical trial. The trials involved 25,800 subjects, the largest ever conducted in India, in partnership with the Indian Council of Medical Research.

“Today is an important milestone in vaccine discovery, for science and our fight against
coronavirus. With today’s results from our Phase 3 clinical trials, we have now reported data on
our COVID-19 vaccine from Phase 1, 2, and 3 trials involving around 27,000 participants.
COVAXIN® demonstrates high clinical efficacy trend against COVID-19 but also significant
immunogenicity against the rapidly emerging variants,” said Dr. Krishna Ella, Chairman & Managing Director, Bharat Biotech.

BBV152 contains a whole virion inactivated SARS-CoV-2 vaccine, which is produced in Vero cells. It is stable at 2 to 8°C (refrigerated) and is shipped in a ready-to-use liquid formulation that permits distribution using existing vaccine supply chain channels.

BBV152 has a 28-day open vial policy as a unique product characteristic, thus reducing vaccine wastage by
approximately 10-30%.
BBV152 is based on an established manufacturing platform with a better safety profile when
compared to other vaccine platforms. The inclusion of the Algel-IMDG adjuvant enhances T-cell
immune responses to COVID-19, leading to long-term protection.

“I want to thank every one of the participants, who volunteered to participate in this vital clinical trial, our partners, principal investigators across 25 study sites, and our team at Bharat Biotech who dedicated their time to this vaccine discovery,” said Mrs. Suchitra Ella, Joint
Managing Director, Bharat Biotech. “We could not have achieved this public-private
partnership milestone without the relentless commitment of those involved.”

Interim Phase 3 Results: 81% Efficacy

The Phase 3 study enrolled 25,800 participants between 18-98 years of age, including 2,433 over the age of 60 and 4,500 with comorbidities. The primary endpoint of Phase 3 clinical trial is
based on the first occurrence of PCR-confirmed symptomatic (mild, moderate, or severe)
COVID-19 with onset at least 14 days after the second study vaccination in serologically
negative (to SARS-CoV-2) adult participants at baseline.

The first interim analysis is based on 43 cases, of which 36 cases of COVID-19 were observed in the placebo group versus 7 cases observed in the BBV152 (COVAXIN®) group, resulting in a point estimate of vaccine efficacy of 80.6%.
The interim analysis included a preliminary review of the safety database, which showed that
severe, serious, and medically attended adverse events occurred at low levels and were balanced between vaccine and placebo groups. The trial’s conduct and monitoring are as per
Good Clinical Practice guidelines and have been outsourced to IQVIA.

Analysis from the National Institute of Virology indicates that vaccine-induced antibodies can neutralize the UK variant strains and other heterologous strains, which has been published in
bioRxiv.
https://doi.org/10.1101/2021.01.26.426986

Bharat Biotech expects to share further details of the trial results as additional data become
available. An additional interim analysis is planned for 87 cases, and the final analysis is planned
for 130 cases. All data from the second interim and final analyses will be shared via pre￾publication servers as well as submitted to a peer-reviewed journal for publication.

More than 40 countries globally have expressed their interest in COVAXIN®. These countries are
highly satisfied with the safe, inactivated vaccine technology and robust data package for safety
and immunogenicity

City Today News
9341997936